When Leen Kawas led Athira Pharma to its IPO in 2020, she wasn’t chasing headlines. She was executing a strategy—one that had been built patiently, piece by piece, over years of research, investment, and preparation. By the time Athira rang the bell, the company had raised over $400 million and become one of the few biotech firms led by a female founder to reach public markets. But for Kawas, the milestone wasn’t the finish line. It was a pivot.
As a scientist-turned-entrepreneur, Kawas approached the IPO not as an end goal, but as a funding event. She viewed it through a pragmatic lens: an opportunity to expand access to capital, build trust with institutional investors, and sustain momentum through later-stage clinical trials. It was never just about valuation. It was about velocity—moving a promising therapeutic pipeline closer to market, without compromising its integrity.
The decision to go public was not made in isolation. Kawas and her team had already laid the groundwork: rigorous preclinical data, a focused pipeline, and a clear regulatory path. But the broader context mattered too. In biotech, timing is currency. Public markets were receptive, interest in neurodegenerative disease was growing, and Athira’s profile aligned with investor appetite for long-term innovation rather than short-term gain.
That alignment was intentional. Leen Kawas understood that a successful IPO depended not just on science, but on narrative. The company had to tell its story in a way that bridged the technical and the human. Investors needed to understand the scientific rationale and the commercial vision. Regulators needed clarity. Analysts needed metrics. Kawas worked to ensure that each audience heard what they needed without diluting the message.
She also brought discipline to the decision-making process. The IPO filing wasn’t rushed. Milestones were met before capital was raised. Investor materials were grounded in data. Kawas believed that trust is earned early, and that credibility is one of a biotech leader’s most valuable assets—especially in public markets, where transparency becomes non-negotiable.
One of her key insights was that going public doesn’t transform a company—it reveals it. The scrutiny intensifies. The reporting requirements sharpen. The ability to communicate with precision becomes central to leadership. Kawas embraced that challenge. She treated it as a shift in role: from builder to steward.
This stewardship extended beyond financial performance. She remained focused on the scientific mission, even as the company scaled. That balance—between advancing therapeutic innovation and managing public expectations—required constant calibration. Kawas didn’t view it as a tradeoff. She viewed it as a responsibility.
The strategic moves surrounding the IPO also reflected her broader view of capital. Kawas does not see funding as fuel alone. She sees it as alignment. A well-structured cap table, supportive investors, and disciplined burn rate are not back-office concerns. They are leadership priorities. For her, equity is a tool—not just to grow, but to protect the company’s core purpose.
Since Athira, Kawas has continued to shape how emerging life sciences firms think about growth. Through her work at Propel Bio Partners and her leadership at EIT Pharma, she advises early-stage companies on how to prepare—not just to raise money, but to grow into it. She brings a founder’s lens to venture capital, emphasizing that capital alone cannot compensate for unclear strategy or weak execution.
Her own IPO journey gives her the credibility to speak candidly. She knows the pressure that builds during roadshows. She knows how quickly investor sentiment can shift. She understands that not every promising company should go public, and that the readiness checklist includes more than trial data. Governance, pipeline durability, and market positioning all matter.
But she also believes in the power of public markets when used wisely. The visibility, access, and validation that come with an IPO can propel a company forward—if leadership is prepared to deliver. That preparation, she argues, begins long before an S-1 is filed. It starts with culture. With clarity of mission. With confidence in what the company brings to the world.
Leen Kawas didn’t just lead Athira to an IPO. She showed what it looks like when science, strategy, and leadership move in sync. Her approach was not flashy. It was measured. And in an industry where timelines stretch long and stakes run high, that kind of steady execution is what builds value that lasts.
Learn more about Leen Kawas through her interview with Billion Success: